Teva triumphs in Ratiopharm battle
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries has fought off competition from Pfizer and Actavis to acquire the German generics maker Ratiopharm for €3.63 billion. The deal ended a nine-month long auction for the company and will cement Teva's position in the European generics market.